New medicines for lung scarring in scleroderma
Official title: Novel compounds for the treatment of systemic sclerosis-associated interstitial lung disease
Funded at Eydis Bio, INC. · NIH-11136500 · Data updated 2026-11-12
This project is developing a new medicine to help people with lung scarring caused by scleroderma, a condition called SSc-ILD.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Eydis Bio, INC. NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project start | July 15, 2024 |
| Project end | June 30, 2027 |
| Funding year | 2025 |
| Award (this year) | $1,417,658 |
| NIH project number | 5R44HL170834-02 |
| Project ID | NIH-11136500 on NIH RePORTER |
Who could benefit from this research
✓Could help
This early-stage research is not yet recruiting patients, but it is focused on developing therapies for individuals diagnosed with systemic sclerosis-associated interstitial lung disease (SSc-ILD).
✕Less likely to help
Patients without SSc-ILD would not directly benefit from this specific treatment, as it is designed for the unique mechanisms of this lung condition.
What this research studies
Systemic sclerosis-associated interstitial lung disease (SSc-ILD) is a serious condition where lung tissue becomes scarred, and current treatments have limitations. Our team has found a key target called TAK1 that plays a role in the inflammation and scarring seen in SSc-ILD. We are developing a new oral medicine, HS-276, that specifically blocks TAK1. Early laboratory tests show that HS-276 can reduce scarring signals in human lung cells and lessen inflammation, and it has also shown promise in animal models of lung scarring. We aim to further develop this promising compound as a potential new treatment option.
Why it matters
Potential benefit: If successful, this new medicine could offer a more effective and safer treatment option for patients living with SSc-ILD, potentially slowing the progression of lung scarring and improving their quality of life.
How similar studies have gone: While TAK1 has been identified as a target in other fibrotic diseases, this specific compound (HS-276) and its application to SSc-ILD represent a novel approach building on promising preclinical findings.
Where this research is happening
-
Eydis Bio, INC.
Durham, United States Active
Researchers
- Principal investigator: Scarneo, Scott — Eydis Bio, INC.
- Study coordinator: Scarneo, Scott
Related research
Other NIH-funded projects on the same topics.
-
Understanding how a cell protein (SLC9A1) drives skin and lung scarring in systemic sclerosis
A five-year NIH grant aims to understand how a specific cell protein called SLC9A1 influences scar-forming cells in systemic sclerosis and related lung disease, with the goal of finding possible therapies.
-
From proteins and genes to new treatments for scar-related lung disease
A large NIH grant is working to map the proteins in the lungs of people with systemic sclerosis to find new targets for drugs that could slow or stop lung fibrosis.
-
Vasculopathy in Systemic Sclerosis and Lung Disease in Adults
A study in adults with systemic sclerosis will look at how blood vessels in the lungs and body relate to the development of lung disease, with the aim of finding new ways to prevent it.
-
Functional markers to guide treatment in systemic sclerosis–related lung disease
A research grant at USC is studying blood biomarkers that show whether medicines are helping people with systemic sclerosis–related interstitial lung disease.
-
Systemic sclerosis-related lung disease: who’s at risk and what blood markers hint at it
A dedicated research grant asks how to identify which people with systemic sclerosis will develop interstitial lung disease and which blood biomarkers can signal that risk.
-
New treatments for lung scarring in systemic sclerosis
This project looks for new drug targets and therapies to help people with systemic sclerosis who have scarring in their lungs.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.